Drug Trial Radar · NCT04201093
Fixed-Dose Trial in Early Parkinson's Disease (PD)
Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
529
Actual
Start
Dec 13, 2019
Primary completion
Jun 28, 2024
Study completion Jun 28, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
Conditions
- Parkinson Disease
Interventions
TavapadonDrug
Participants will be randomized to receive tavapadon 5mg tablet once daily orally for 27 weeks.
PlaceboDrug
Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
TavapadonDrug
Participants will be randomized to receive tavapadon 15mg tablet once daily orally for 27 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the MDS-UPDRS Parts II and III Combined ScoreTime frame: Week 26
Locations
77 sites in 12 countries. Site status is shown where the registry gives one.
Birmingham, Alabama
Birmingham, Alabama
Little Rock, Arkansas
Little Rock, Arkansas
Fountain Valley, California
Fountain Valley, California
Los Angeles, California
Los Angeles, California
Pasadena, California
Pasadena, California
Englewood, Colorado
Englewood, Colorado
Adventura, Florida
Adventura, Florida
Boca Raton, Florida
Boca Raton, Florida
Tampa, Florida
Tampa, Florida
Augusta, Georgia
Augusta, Georgia
Savannah, Georgia
Savannah, Georgia
Chicago, Illinois
Chicago, Illinois
Kansas City, Kansas
Kansas City, Kansas
Scarborough, Maine
Scarborough, Maine
Boston, Massachusetts
Boston, Massachusetts
East Lansing, Michigan
East Lansing, Michigan
Las Vegas, Nevada
Las Vegas, Nevada
Asheville, North Carolina
Asheville, North Carolina
Durham, North Carolina
Durham, North Carolina
Columbus, Ohio
Columbus, Ohio
Toledo, Ohio
Toledo, Ohio
Philadelphia, Pennsylvania
Philadelphia, Pennsylvania
Georgetown, Texas
Georgetown, Texas
Houston, Texas
Houston, Texas
Lubbock, Texas
Lubbock, Texas
Burlington, Vermont
Burlington, Vermont
Virginia Beach, Virginia
Virginia Beach, Virginia
Erina, New South Wales
Erina, New South Wales, Australia
Woolloongabba, Queensland
Woolloongabba, Queensland, Australia
Parkville, Victoria
Parkville, Victoria, Australia
Medical center VITA1, Pleven
Pleven, Bulgaria
Pleven, Bulgaria
Pleven, Bulgaria
Pleven
Pleven, Bulgaria
Multiprofile Hospital, Sofia
Sofia, Bulgaria
Sofia
Sofia, Bulgaria
Sofia
Sofia, Bulgaria
DCC Neoclinic
Sofia, Bulgaria
Sofia
Sofia, Bulgaria
Ottawa, Ontario
Ottawa, Ontario, Canada
Toronto, Ontario
Toronto, Ontario, Canada
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.